COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00066417
Recruitment Status : Terminated (Trial was withdrawn for drug availability issues.)
First Posted : August 7, 2003
Last Update Posted : May 1, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

PURPOSE: This phase II trial is studying how well peripheral stem cell transplant works in treating patients with high-risk leukemia.

Condition or disease Intervention/treatment Phase
Chronic Myeloproliferative Disorders Leukemia Myelodysplastic/Myeloproliferative Diseases Drug: cyclophosphamide Drug: cyclosporine Drug: fludarabine phosphate Drug: methylprednisolone Drug: therapeutic allogeneic lymphocytes Drug: thiotepa Procedure: allogeneic bone marrow transplantation Procedure: biological therapy Procedure: bone marrow ablation with stem cell support Procedure: bone marrow transplantation Procedure: chemotherapy Procedure: leukocyte therapy Procedure: non-specific immune-modulator therapy Procedure: peripheral blood lymphocyte therapy Procedure: peripheral blood stem cell transplantation Procedure: radiation therapy Phase 2

Detailed Description:


  • Determine the safety of a preparative regimen comprising total body irradiation, cyclophosphamide, thiotepa, and fludarabine, but without anti-thymocyte globulin, in patients with high-risk leukemia treated with peripheral blood stem cell transplantation from partially matched related donors.
  • Determine the incidence of graft failure, acute graft-versus-host disease (GVHD), and treatment-related mortality in patients treated with this regimen.
  • Determine rates of chronic GVHD and relapse in patients treated with this regimen.
  • Determine disease-free and overall survival in patients treated with this regimen.

OUTLINE: This is a pilot study.

Patients receive a preparative regimen comprising total lymphoid irradiation once daily on days -13 to -11; cyclophosphamide IV over 1 hour on days -8 and -7; thiotepa IV over 4 hours every 12 hours on day -6; fludarabine IV over 30 minutes on days -5 to -1; and total body irradiation once on day -1. Patients also receive cyclosporine IV over 12 hours on days -8 to -1 and methylprednisolone IV twice daily on days -3 and -2. Patients receive CD34-enriched T-cell-depleted allogeneic stem cell infusion on day 0.

Patients with disease progression or uncontrolled infection but without grade II or greater graft-versus-host disease may receive up to 3 donor lymphocyte infusions at least 4 weeks apart until disease regression.

Patients are followed at least weekly until day 100 and then at 6, 12, 18, 24, 36, and 48 months.

PROJECTED ACCRUAL: A total of 20-51 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 51 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study Of T-Cell-Depleted Peripheral Blood Stem Cell Transplantation From Partially Matched Related Donors For Patients With High-Risk Leukemia
Actual Study Completion Date : January 2007

Primary Outcome Measures :
  1. Incidence of graft failure 100 days post-transplant
  2. Incidence of acute and chronic graft-vs-host disease100 days post-transplant
  3. Transplant-related mortality 100 days post-transplant
  4. Disease-free survival 100 days post-transplant
  5. Overall survival 100 days post-transplant

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   10 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of 1 of the following:

    • High-risk myelodysplastic syndromes (MDS), meeting 1 of the following criteria:

      • Transformation to acute leukemia defined by at least 15% blasts
      • Secondary to prior treatment with chemotherapy and/or radiotherapy
      • Presence of complex cytogenetics (at least 3 karyotypic abnormalities)
      • Monosomy or deletion of chromosome 7
    • Acute myeloid leukemia (AML), meeting 1 of the following criteria :

      • High-risk AML in first remission and meeting 1 of the following criteria:

        • At least 3 karyotypic abnormalities
        • Monosomy or deletion of chromosome 5 or 7 = 11q23 chromosomal abnormality
        • Prior diagnosis of MDS
        • Received prior radiotherapy or chemotherapy
      • In second or subsequent remission
      • Primary induction failure or partial remission
      • Untested or sensitive relapse
    • Chronic myelogenous leukemia, meeting 1 of the following criteria:

      • Blast crisis
      • Accelerated phase disease that has failed prior treatment with imatinib mesylate, defined as a failure to achieve hematologic response after 3 months of standard dose (600 mg/day) therapy or disease progression on therapy
    • Myeloproliferative disease

      • The following diagnoses are eligible:

        • Agnogenic myeloid metaplasia
        • Essential thrombocythemia
        • Polycythemia vera
      • Must have evidence of transformation to acute leukemia
    • Acute lymphocytic leukemia (ALL), meeting 1 of the following criteria:

      • High-risk ALL in first remission defined by 1 of the following:

        • t(9;22) or 11q23 chromosomal abnormality
        • Complete response at least 4 weeks after induction therapy OR requiring at least 2 induction regimens
      • Second or subsequent remission
  • No relapsed leukemia refractory to appropriate salvage therapy
  • Availability of an HLA-mismatched family donor

    • Donor age 75 or under
  • No better donor alternative (i.e., HLA-matched related or unrelated stem cell donor) is available



  • 10 to 50

Performance status

  • ECOG 0-1

Life expectancy

  • More than 3 months


  • See Disease Characteristics


  • Bilirubin no greater than 4 mg/dL
  • Transaminases no greater than 3 times upper limit of normal


  • Creatinine no greater than 2.0 mg/dL OR
  • Creatinine clearance at least 60 mL/min


  • LVEF at least 40%


  • DLCO at least 65% of predicted


  • Not pregnant
  • Negative pregnancy test
  • HIV negative
  • No other prior malignancy except basal cell or squamous cell skin cancer or a remote history of cancer now considered cured
  • No major organ dysfunction that would preclude transplantation
  • No major anticipated illness or organ failure that would preclude transplantation
  • No severe psychiatric illness or mental deficiency that would preclude giving informed consent or complying with study
  • No uncontrolled infection


Biologic therapy

  • Not specified


  • See Disease Characteristics

Endocrine therapy

  • Not specified


  • See Disease Characteristics


  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00066417

Layout table for location information
United States, Maryland
NIH - Warren Grant Magnuson Clinical Center
Bethesda, Maryland, United States, 20892-1182
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
Study Chair: Bipin N. Savani, MD National Heart, Lung, and Blood Institute (NHLBI)
Layout table for additonal information Identifier: NCT00066417    
Obsolete Identifiers: NCT00062725
Other Study ID Numbers: CDR0000315900
First Posted: August 7, 2003    Key Record Dates
Last Update Posted: May 1, 2013
Last Verified: November 2006
Keywords provided by National Cancer Institute (NCI):
essential thrombocythemia
polycythemia vera
blastic phase chronic myelogenous leukemia
secondary myelodysplastic syndromes
previously treated myelodysplastic syndromes
adult acute myeloid leukemia in remission
childhood acute myeloid leukemia in remission
de novo myelodysplastic syndromes
secondary acute myeloid leukemia
accelerated phase chronic myelogenous leukemia
childhood chronic myelogenous leukemia
adult acute lymphoblastic leukemia in remission
childhood acute lymphoblastic leukemia in remission
recurrent adult acute myeloid leukemia
relapsing chronic myelogenous leukemia
recurrent childhood acute myeloid leukemia
chronic idiopathic myelofibrosis
atypical chronic myeloid leukemia
myelodysplastic/myeloproliferative disease, unclassifiable
adult acute myeloid leukemia with t(8;21)(q22;q22)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with t(15;17)(q22;q12)
Additional relevant MeSH terms:
Layout table for MeSH terms
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Fludarabine phosphate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Enzyme Inhibitors
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Calcineurin Inhibitors